{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:22:07Z","timestamp":1756902127032,"version":"3.44.0"},"reference-count":23,"publisher":"The Pediatric Pharmacy Association","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Arginine vasopressin (AVP) is the primary regulator of free water retention through its interactions with the AVP type 2 receptor (V2). As opposed to the natriuresis and diuresis that occur with loop and thiazide diuretics, conivaptan is an AVP V1A\/V2 receptor antagonist, which enhances free water excretion while minimizing sodium loss. We report our preliminary experience with conivaptan to promote diuresis in infants with functional or structural cardiac disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>A retrospective cohort study was conducted of infants who had received conivaptan from August 2007 to January 2008. A loading dose of conivaptan (0.3-0.6 mg\/kg) was followed by a continuous infusion of 0.01-0.02 mg\/kg\/hr for 24 hours. Sodium, potassium, chloride, blood urea nitrogen (BUN), creatinine, bicarbonate, and urine output were measured prior to the start of conivaptan and at 24 hours after initiation of the infusion.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Conivaptan was administered intravenously on 6 occasions to 5 patients with hypervolemic hyponatremia. Patients ranged in age from 8 to179 days, and body weight ranged from 3 to 4.12 kg. Mean sodium concentration increased from 130.17 \u00b1 1.94 mEq\/L to 133.67 \u00b1 3.88 mEq\/L (p=0.048), and median urine output increased from 4.15 to 5.05 mL\/kg\/hr (p=0.286). No significant changes were noted in serum potassium, bicarbonate, creatinine, or BUN. No adverse effects were noted during conivaptan infusion.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSION<\/jats:title>\n                  <jats:p>Intravenous conivaptan is effective for increasing serum sodium levels and may be a potential adjuvant to enhance diuresis in children with cardiac disease. Given the potential benefits of conivaptan compared to diuretic therapy, with all their potential complications, prospective trials are warranted.<\/jats:p>\n               <\/jats:sec>","DOI":"10.5863\/1551-6776-17.1.78","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T19:46:58Z","timestamp":1603828018000},"page":"78-83","source":"Crossref","is-referenced-by-count":1,"title":["Initial Experience With Conivaptan Use in Critically Ill Infants With Cardiac Disease"],"prefix":"10.5863","volume":"17","author":[{"given":"Ryan C","family":"Jones","sequence":"first","affiliation":[{"name":"Le Bonheur Children's Hospital, Memphis, Tennessee"},{"name":"Department of Pediatrics, College of Medicine, The University of Tennessee Health Science Center, Memphis, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surender","family":"Rajasekaran","sequence":"additional","affiliation":[{"name":"Helen DeVos Children's Hospital, Division of Pediatric Critical Care, Grand Rapids, Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark Rayburn","family":"PharmD","sequence":"additional","affiliation":[{"name":"Le Bonheur Children's Hospital, Memphis, Tennessee"},{"name":"Department of Clinical Pharmacy, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph D","family":"Tobias","sequence":"additional","affiliation":[{"name":"Nationwide Children's Hospital and Department of Anesthesiology, The Ohio State University, Columbus, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M","family":"Kelsey","sequence":"additional","affiliation":[{"name":"Le Bonheur Children's Hospital, Memphis, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn T","family":"Wetzel","sequence":"additional","affiliation":[{"name":"Le Bonheur Children's Hospital, Memphis, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio G","family":"Cabrera","sequence":"additional","affiliation":[{"name":"Texas Children's Hospital, Department of Pediatrics, Baylor College of Medicine, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"key":"2020102715452462500_i1551-6776-17-1-78-b01","unstructured":"Product information: Vaprisol injection, conivaptan HCl injection. Astellas Pharma US, Inc., Deerfield, IL, May2010."},{"issue":"11","key":"2020102715452462500_i1551-6776-17-1-78-b02","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1161\/hc1102.105264","article-title":"BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy","volume":"105","author":"Gottlieb","year":"2002;","journal-title":"Circulation"},{"key":"2020102715452462500_i1551-6776-17-1-78-b03","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/0002-8703(94)90130-9","article-title":"Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis","volume":"127","author":"Connelly","year":"1994;","journal-title":"Am Heart J"},{"issue":"3","key":"2020102715452462500_i1551-6776-17-1-78-b04","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1651-2227.1987.tb10487.x","article-title":"Hyponatraemia in premature babies and following surgery in older children","volume":"76","author":"Judd","year":"1987;","journal-title":"Acta Paediatr Scand"},{"issue":"1","key":"2020102715452462500_i1551-6776-17-1-78-b05","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0002-9629(15)40677-9","article-title":"Treatment of edematous disorders with diuretics","volume":"319","author":"Rasool","year":"2000;","journal-title":"Am J Med Sci"},{"issue":"6","key":"2020102715452462500_i1551-6776-17-1-78-b06","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/CRD.0b013e3181f5b3b7","article-title":"Novel agents for the treatment of hyponatremia: a review of conivaptan and tolvaptan","volume":"18","author":"Ferguson-Myrthil","year":"2010;","journal-title":"Cardiol Rev"},{"issue":"8","key":"2020102715452462500_i1551-6776-17-1-78-b07","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s00467-008-0809-y","article-title":"Use of conivaptan to allow aggressive hydration to prevent tumor lysis syndrome in a pediatric patient with large-cell lymphoma and SIADH","volume":"23","author":"Rianthavorn","year":"2008;","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"2020102715452462500_i1551-6776-17-1-78-b08","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.cardfail.2008.06.003","article-title":"Efficacy and safety of the vasopressin V1A\/V2-receptor antagonist conivaptan in acute decompensated heart failure: A dose-ranging pilot study","volume":"14","author":"Goldsmith","year":"2008;","journal-title":"J Card Fail"},{"issue":"1","key":"2020102715452462500_i1551-6776-17-1-78-b09","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1254\/jphs.08R17FM","article-title":"New topics in vasopressin receptors and approach to novel drugs: research and development of conivaptan hydrochloride (YM087), a drug for the treatment of hyponatremia","volume":"109","author":"Arai","year":"2009;","journal-title":"J Pharmacol Sci"},{"issue":"9","key":"2020102715452462500_i1551-6776-17-1-78-b10","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s002280050685","article-title":"Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1\/V2 vasopressin receptor antagonist in normal subjects","volume":"55","author":"Burnier","year":"1999;","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"2020102715452462500_i1551-6776-17-1-78-b11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1152\/physrev.00024.2001","article-title":"Aquaporins in the kidney: from molecules to medicine","volume":"82","author":"Nielsen","year":"2002;","journal-title":"Physiol Rev"},{"issue":"5-6","key":"2020102715452462500_i1551-6776-17-1-78-b12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1046\/j.1440-1681.1999.03045.x","article-title":"Pharmacologic profile or orally administered YM087, a vasopressin antagonist, in conscious rats","volume":"26","author":"Tomura","year":"1999;","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"1","key":"2020102715452462500_i1551-6776-17-1-78-b13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0002-8703(02)94708-3","article-title":"Vasopressin: a new target for the treatment of heart failure","volume":"146","author":"Lee","year":"2003;","journal-title":"Am Heart J"},{"issue":"6","key":"2020102715452462500_i1551-6776-17-1-78-b14","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0735-1097(83)80040-0","article-title":"Increased plasma arginine vasopressin levels in patients with congestive heart failure","volume":"1","author":"Goldsmith","year":"1983;","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2020102715452462500_i1551-6776-17-1-78-b15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1056\/NEJM198107303050506","article-title":"Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure","volume":"305","author":"Szatalowicz","year":"1981;","journal-title":"N Engl J Med"},{"issue":"5","key":"2020102715452462500_i1551-6776-17-1-78-b16","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","article-title":"Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the studies of left ventricular dysfunction (SOLVD)","volume":"82","author":"Francis","year":"1990;","journal-title":"Circulation"},{"issue":"1","key":"2020102715452462500_i1551-6776-17-1-78-b17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00002480-200201000-00007","article-title":"Serial plasma concentrations of atrial natriuretic peptide, plasma renin activity, aldosterone, and antidiuretic hormone in neonates on extracorporeal membrane oxygenation","volume":"48","author":"Semmekrot","year":"2002;","journal-title":"ASAIO J"},{"issue":"1","key":"2020102715452462500_i1551-6776-17-1-78-b18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MAJ.0b013e31817b8148","article-title":"and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia","volume":"337","author":"Annane","year":"2009;","journal-title":"Am J Med Sci"},{"issue":"4","key":"2020102715452462500_i1551-6776-17-1-78-b19","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1345\/aph.1M660","article-title":"Vasopressin antagonists: pharmacotherapy for the treatment of heart failure","volume":"44","author":"Reilly","year":"2010;","journal-title":"Ann Pharmacother"},{"issue":"3-4","key":"2020102715452462500_i1551-6776-17-1-78-b20","first-page":"198","article-title":"Potassium-sparing diuretics","volume":"10","author":"Horisberger","year":"1987;","journal-title":"Ren Physiol"},{"issue":"3","key":"2020102715452462500_i1551-6776-17-1-78-b21","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1388-9842(00)00094-5","article-title":"Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure","volume":"2","author":"Paterna","year":"2000;","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"2020102715452462500_i1551-6776-17-1-78-b22","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0002-9343(98)00365-9","article-title":"Diuretic treatment and diuretic resistance in heart failure","volume":"106","author":"Kr\u00e4mer","year":"1999;","journal-title":"Am J Med"},{"issue":"9A","key":"2020102715452462500_i1551-6776-17-1-78-b23","doi-asserted-by":"crossref","first-page":"2B","DOI":"10.1016\/j.amjcard.2005.03.002","article-title":"Hyponatremia in congestive heart failure","volume":"95","author":"Orem","year":"2005;","journal-title":"Am J Cardiol"}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/17\/1\/78\/1786634\/1551-6776-17_1_78.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/17\/1\/78\/1786634\/1551-6776-17_1_78.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T18:40:23Z","timestamp":1738780823000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/17\/1\/article-p78.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,8,1]]}},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-17.1.78","relation":{},"ISSN":["1551-6776"],"issn-type":[{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2012,8,1]]}}}